Attention-deficit/hyperactivity disorder
Conditions
Interventions
8-week methylphenidate administration
Sponsors
Shimada Ryoiku Center
1.National Center of Neurology and Psychiatry 2.Rissho University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. A patient who is more than 6-yaer old and under 12-year old when informed consent was obtained from their parents or guardians. 2. A patient who is diagnosed to have AD/HD by child psychiatrists or child neurologists based on DSM-IV-TR. 3. A patient whose parents or guradians can give written informed consent.
Exclusion criteria
Exclusion criteria: 1. A patient with severe anxiety or agitation. 2. A patient with glaucoma. 3. A patient with thyroidal dysfunction 4. A patient with arrythmia or abnormal blood pressure. 5. A patient with history of allergic reaction or severe side effects with methylphenidate. 6. A patient with severe mood disorder 7. A patient with motor tics, Tourette's syndrome, or family history of Tourette's syndrome. 8. A patient with pheochromocytoma. 9. A patient who receives medication of MAO inhibitor. 10. A patient with epilepsy. 11. A patient with schizophrenia, psychotic disorders, bipolar disorder. 12. A patient with history of drug abuse or alcohol dependence. 13. A patient with significant mental retardation (FIQ<70, WISC-III).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relation between hemodynamic changes detected by near-infrared spectroscopy and difference of AD/HD symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Assessment of behavioral disturbances(CBCL) 2) Assessment of general function(GAF) 3) Assessment of comorbidities(SCAS,CDRS,PARS) 4) Assessment of self-estimate(JSSC) | — |
Countries
Japan
Contacts
Public ContactHiroshi Ozawa
Shimada Ryoiku Center Department of Pediatrics
Outcome results
None listed